Biyoterörizm Tehdidi, Sağlık Sisteminin Yanıtı ve Gelecek Nesil Müdahale Stratejileri

Abstract

Biyoterörizm kavramını virüs, bakteri, toksin ve mantar gibi mikroorganizmaların kasıtlı yayılımı çerçevesinde tanımlanarak; sağlık çalışanları, araştırmacılar, eczacılar ve düzenleyici otoriteler nezdinde bu tehdide karşı farkındalık oluşturulması hedeflenmiştir. Çalışmada, moleküler biyoloji ve genetik mühendisliğindeki hedefe yönelik ilaç tasarımı ve gen terapisi gibi umut verici gelişmelerin, kötü niyetli kullanım neticesinde biyolojik silah üretimi riskini nasıl tetiklediği incelenmektedir. Bu doğrultuda; biyoterörizmin tarihsel süreci, ajanların sınıflandırılması, Biyolojik Silahlar Sözleşmesi ve biyolojik tehditlere karşı geliştirilen savunma stratejilerinin bütüncül bir yaklaşımla ele alınması hedeflenmektedir. Biyoterörizmle mücadelede biyogüvenlik ve biyoetik kavramlarının stratejik önemi, güncel küresel krizler ışığında daha belirgin hale gelmiştir. Özellikle COVID-19 pandemisi, biyoterör saldırısı perspektifinden değerlendirildiğinde, toplum temelli hazırlık süreçlerinin ve disiplinler arası iş birliğinin hayatiyetini ortaya koymaktadır. Gelecek nesil savunma stratejileri kapsamında, biyosensör tabanlı hızlı tanı sistemleri ve yerli teknoloji uygulamaları, olası tehditlerin erken tespitinde kritik rol oynamaktadır. Ayrıca, mRNA ve Lipid Nanopartikül (LNP) platformlarının sunduğu hızlı ve esnek üretim kapasitesi, biyoterör ajanlarına karşı geliştirilecek modern karşı önlemlerin temelini oluşturmaktadır. Sonuç olarak, genetik düzeydeki bilimsel ilerlemelerin çift yönlü kullanımı (dual-use) kontrol altında tutulmalı ve savunma mekanizmaları teknolojik yeniliklerle sürekli güncellenmelidir.

Keywords

• Biyoterörizm
• Biyolojik savaş ajanları
• Biyosensör
• Lipid nanopartikül
• Covid-19

The Threat of Bioterrorism, The Healthcare System's Response, and Next-Generation Intervention

Abstract

Bioterrorism is defined within the framework of the intentional dissemination of microorganisms such as viruses, bacteria, toxins, and fungi, and to raise awareness of this threat among healthcare professionals, researchers, pharmacists, and regulatory authorities. The study examines how promising developments in molecular biology and genetic engineering—such as targeted drug design and gene therapy—may, if misused, trigger the risk of biological weapon production. In this context, the aim is to address the historical process of bioterrorism, the classification of agents, the Biological Weapons Convention, and the defense strategies developed against biological threats with a holistic approach. The strategic importance of the concepts of biosafety and bioethics in the fight against bioterrorism has become more apparent in light of current global crises. Especially when the COVID-19 pandemic is evaluated from the perspective of a bioterrorism attack, it underscores the vital importance of community-based preparedness processes and interdisciplinary collaboration. Within the scope of next-generation defense strategies, biosensor-based rapid diagnostic systems and domestic technology applications play a critical role in the early detection of potential threats. Furthermore, the rapid and flexible production capacity offered by mRNA and Lipid Nanoparticle (LNP) platforms forms the foundation of modern countermeasures to be developed against bioterrorism agents. In conclusion, the dual-use of scientific advancements at the genetic level should be kept under control, and defense mechanisms must be continuously updated with technological innovations.

Keywords

• Bioterrorism
• Biological warfare agents
• Biosensor
• Lipid nanoparticles

References

1. [1] Balram Rathish, Arun Wilson, and Vijay Vasudev Pillay, “Comprehensive Review of Bioterrorism.” Accessed: Feb. 05, 2026. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK570614/
2. [2] O. Xu, “Impacts and lessons learned from coronavirus-19 pandemic in the United States: preparing for future public health emergencies,” Health Econ Rev, vol. 15, no. 1, p. 77, Oct. 2025.
3. [3] N. A. Rathjen and S. D. Shahbodaghi, “Bioterrorism,” Am Fam Physician, vol. 104, no. 4, pp. 376–385, Oct. 2021.
4. [4] H. J. Jansen, F. J. Breeveld, C. Stijnis, and M. P. Grobusch, “Biological warfare, bioterrorism, and biocrime,” Clinical Microbiology and Infection, vol. 20, no. 6, pp. 488–496, Jun. 2014.
5. [5] M. Oliveira, G. Mason-Buck, D. Ballard, W. Branicki, and A. Amorim, “Biowarfare, bioterrorism and biocrime: A historical overview on microbial harmful applications,” Forensic Science International, vol. 314, p. 110366, Sep. 2020.
6. [6] “COVID-19 Bilgilendirme Platformu- Pandemi,” T.C. Sağlık Bakanlığı. [Online]. Available: https://covid19.saglik.gov.tr/TR-66494/pandemi.html
7. [7] “COVID-19 AŞISI BİLGİLENDİRME PLATFORMU- Aşı Sözlüğü-Epidemi (Salgın),” T.C. SAĞLIK BAKANLIĞI. [Online]. Available: https://covid19asi.saglik.gov.tr/TR-78038/epidemi-salgin.html
8. [8] R. Bhatia, “Addressing challenge of zoonotic diseases through One Health approach,” Indian Journal of Medical Research, vol. 153, no. 3, pp. 249–252, Mar. 2021.

9. [9] A. Schiller, A. Saidouni, H. Mahrous, M. Elhakim, and A. Elkholy, “One Health best practices for addressing health threats at the human–animal–environment interface, with focus on the Eastern Mediterranean Region,” Transactions of The Royal Society of Tropical Medicine and Hygiene, vol. 120, no. 3, pp. 192–198, Mar. 2026.
10. [10] M. Giangaspero, S. Al Mahdhouri, S. Al Bulushi, M. K. Al-Ghafri, and P. Turno, “Transboundary Diseases and One Health Approach Implications for Global Health Threats, with Particular Interest in Conservation and Bioterrorism,” Pathogens, vol. 14, no. 12, p. 1193, Nov. 2025.
11. [11] “About One Health,” U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION. [Online]. Available: https://www.cdc.gov/one-health/about/index.html
12. [12] D. S. Schmeller, F. Courchamp, and G. Killeen, “Biodiversity loss, emerging pathogens and human health risks,” Biodivers Conserv, vol. 29, no. 11–12, pp. 3095–3102, Oct. 2020.
13. [13] A. Kotwal and A. Yadav, “Biothreat & One Health: Current scenario & way forward,” Indian Journal of Medical Research, vol. 153, no. 3, pp. 257–263, Mar. 2021.
14. [14] V. Radosavijevic, “Environmental Health and Bioterrorism,” in Encyclopedia of Environmental Health, Elsevier, pp. 392–399, 2011.
15. [15] World Health Organization, Taking a multisectoral one health approach: a tripartite guide to addressing zoonotic diseases in countries. Food & Agriculture Org., 2019.
16. [16] W. E. Grunden and O. H. Tuovinen, “Legacy and impact of the 1925 Geneva Protocol: one hundred years of treaties and debates on chemical and biological weapons,” Front. Microbiol., vol. 16, p. 1685967, Dec. 2025.
17. [17] Biological Weapons Convention, “Biological Weapons Convention, U.S. Department of State . Accessed September 15, 2022.” [Online]. Available: https://www.state.gov/biological-weapons-convention/
18. [18] S. Das and V. Kataria, “Bioterrorism : A Public Health Perspective,” Medical Journal Armed Forces India, vol. 66, no. 3, pp. 255–260, Jul. 2010.
19. [19] “Mission A world free of chemical weapons,” Organisation for the Prohibition of Chemical Weapons. [Online]. Available: https://www.opcw.org/about-us/mission
20. [20] “1540 Committee Security Council Committee established pursuant to resolution 1540 (2004),” United Nations. [Online]. Available: https://www.un.org/en/sc/1540/faq.shtml#1
21. [21] M. G. Kortepeter and G. W. Parker, “Potential Biological Weapons Threats,” Emerg. Infect. Dis., vol. 5, no. 4, pp. 523–527, Aug. 1999.
22. [22] E. Geissler, Prevention of a biological and toxin arms race and the responsibility of scientists. Berlin: Akademie Verl, 1991.
23. [23] S. Wilcox, M. H. R. C., “Agents of biological warfare,” REVIEWS IN MEDICAL MICROBIOLOGY, vol. 4(3), pp. 138–143, Jul. 1993.
24. [24] D. K. J. E. Von Lubitz, Bioterrorism: field guide to disease identification and initial patient management. Boca Raton, FL: CRC Press, 2004.
25. [25] K. Alibek, Biohazard: the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it. New York: Random House, 1999.
26. [26] Selçuk KILIÇ, “BİYOLOJİK SİLAHLAR ve BİYOTERÖRİZM,” Türk Hij Den Biyol Derg, vol. Cilt 63, no. No 1,2,3, p. S : 1-20, 2006.
27. [27] F. Vatansever et al., “Can biowarfare agents be defeated with light?,” Virulence, vol. 4, no. 8, pp. 796–825, Nov. 2013.
28. [28] R. M. Atlas, “The Medical Threat of Biological Weapons,” Critical Reviews in Microbiology, vol. 24, no. 3, pp. 157–168, Jan. 1998.
29. [29] R. C. Spencer and N. F. Lightfoot, “Preparedness and Response to Bioterrorism,” Journal of Infection, vol. 43, no. 2, pp. 104–110, Aug. 2001.
30. [30] W. D. Burrows and S. E. Renner, “Biological warfare agents as threats to potable water.,” Environ Health Perspect, vol. 107, no. 12, pp. 975–984, Dec. 1999.
31. [31] L. S. Jeffrey, Medical aspects of chemical and biological warfare. Place of publication not identified: U S Govt. Printing Office, 1997.
32. [32] M. Schaechter, N. C. Engleberg, V. J. DiRita, and T. Dermody, Schaechter’s mechanisms of microbial disease, 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013.
33. [33] International Society for Infectious Diseases, “International Society for Infectious Diseases Program for Monitoring Emerging Diseases. Accessed October 4, 2022.” [Online]. Available: https://promedmail.org/
34. [34] AFAD, “Halk Tarafından Alınacak Tedbirler,” AFAD. Accessed: Feb. 05, 2026. [Online]. Available: https://www.afad.gov.tr/halk-tarafindan-alinacak-tedbirler
35. [35] M. S. Selda Sayın KUTLU, “Bioterrorism and anthrax,” Turkish Journal of Emergency Medicine, vol. Volume 9, no. Issue 4, pp. 185–190, 2009.
36. [36] K. Krishan, B. Kaur, and A. Sharma, “India’s Preparedness against Bioterrorism:Biodefence Strategies and Policy Measures,” Current Science, vol. 113, no. 09, p. 1675, Nov. 2017.
37. [37] J. L. Bird, “FORENSIC USE OF RAPD ANALYSIS IN THE INVESTIGATION OF BIOTERRORISM,” MSc Thesis, University of Kansas, Lawrence, KS, 2003.
38. [38] M. Lindström, R. Keto, A. Markkula, M. Nevas, S. Hielm, and H. Korkeala, “Multiplex PCR Assay for Detection and Identification of Clostridium botulinum Types A, B, E, and F in Food and Fecal Material,” Appl Environ Microbiol, vol. 67, no. 12, pp. 5694–5699, Dec. 2001.
39. [39] D. V. Lim, J. M. Simpson, E. A. Kearns, and M. F. Kramer, “Current and Developing Technologies for Monitoring Agents of Bioterrorism and Biowarfare,” Clin Microbiol Rev, vol. 18, no. 4, pp. 583–607, Oct. 2005.
40. [40] L. Song, S. Ahn, and D. R. Walt, “Detecting Biological Warfare Agents,” Emerg. Infect. Dis., vol. 11, no. 10, pp. 1629–1632, Oct. 2005.
41. [41] E. T. Lagally et al., “Integrated Portable Genetic Analysis Microsystem for Pathogen/Infectious Disease Detection,” Anal. Chem., vol. 76, no. 11, pp. 3162–3170, Jun. 2004.
42. [42] G. Fresco-Cohen, L. I., “BioPen Senses BioThreats,” The Future of Things Archived, Apr. 2015.
43. [43] G. D. Koblentz and J. B. Tucker, “Tracing an Attack: The Promise and Pitfalls of Microbial Forensics,” Survival, vol. 52, no. 1, pp. 159–186, Mar. 2010.
44. [44] O. Grundmann, “The current state of bioterrorist attack surveillance and preparedness in the US,” RMHP, p. 177, Oct. 2014.
45. [45] T. U. G. Mir, A. K. Wani, N. Akhtar, and S. Shukla, “CRISPR/Cas9: Regulations and challenges for law enforcement to combat its dual-use,” Forensic Science International, vol. 334, p. 111274, May 2022.
46. [46] A. K. Wani et al., “Genome centric engineering using ZFNs, TALENs and CRISPR-Cas9 systems for trait improvement and disease control in Animals,” Vet Res Commun, vol. 47, no. 1, pp. 1–16, Jan. 2023.
47. [47] P. Mehrotra, “Biosensors and their applications – A review,” Journal of Oral Biology and Craniofacial Research, vol. 6, no. 2, pp. 153–159, May 2016.
48. [48] C. I. L. Justino, A. C. Duarte, and T. A. P. Rocha-Santos, “Critical overview on the application of sensors and biosensors for clinical analysis,” TrAC Trends in Analytical Chemistry, vol. 85, pp. 36–60, Dec. 2016.
49. [49] İdil Karaca Açarı, “Bölüm 11: Biyosensörler,” in Matematik ve Fen Bilimleri Üzerine Araştırmalar, Özgür Yayınları, 2023.
50. [50] G.-P. Nikoleli et al., “Biosensors for Security and Bioterrorism: Definitions, History, Types of Agents, New Trends and Applications,” in Biosensors for Security and Bioterrorism Applications, D. P. Nikolelis and G.-P. Nikoleli, Eds., in Advanced Sciences and Technologies for Security Applications, Cham: Springer International Publishing, 2016, pp. 1–13.
51. [51] H. Kumar and R. Rani, “Development of Biosensors for the Detection of Biological Warfare Agents: Its Issues and Challenges,” Science Progress, vol. 96, no. 3, pp. 294–308, Sep. 2013.
52. [52] S. A. Glazier and H. H. Weetall, “Autoflurosecence detection of Escherichia coli on silver membrane filters,” Journal of Microbiological Methods, vol. 20, no. 1, pp. 23–27, Jun. 1994.
53. [53] B.-K. Oh, W. Lee, B. S. Chun, Y. M. Bae, W. H. Lee, and J.-W. Choi, “The fabrication of protein chip based on surface plasmon resonance for detection of pathogens,” Biosensors and Bioelectronics, vol. 20, no. 9, pp. 1847–1850, Mar. 2005.
54. [54] Z. Tüylek, “Sağlıkta biyosensörler: Yapı, uygulamalar, zorluklar ve gelecek perspektifleri,” BAUN Fen. Bil. Enst. Dergisi, vol. 28, no. 1, pp. 39–55, Dec. 2025.
55. [55] A. Bilir, M. Yavuz, U. O. S. Seker, and S. Dumanli, “Wireless in-body sensing through genetically engineered bacteria,” Nat Commun, vol. 16, no. 1, p. 10432, Nov. 2025.
56. [56] G. Vardar and F. Hanikoğlu, “Biyosensörler ve Biyokimya Alanındaki Uygulamaları,” in Güncel Biyokimya Çalışmaları IV, Akademisyen Kitabevi, 2022, pp. 65–80.
57. [57] G. Suna, S. Gunduz, S. Topal, T. Ozturk, and E. Karakuş, “A unique triple–channel fluorescent probe for discriminative detection of cyanide, hydrazine, and hypochlorite,” Talanta, vol. 257, p. 124365, May 2023.
58. [58] “Pent-AGON,” AGON Biotechnology LLC. Accessed: Jan. 30, 2026. [Online]. Available: https://agonbiotechnology.com/urunler/bakteri-sensorleri/
59. [59] “Ürünler,” NANObiz Teknıloji A.Ş. Accessed: Jan. 31, 2026. [Online]. Available: https://www.nanobiz.com.tr
60. [60] “Proje Destekleri,” TÜSEB. Accessed: Jan. 30, 2026. [Online]. Available: https://www.tuseb.gov.tr
61. [61] “On İkinci Kalkınma Planı,” T.C. Strateji ve Bütçe Başkanlığı. Accessed: Jan. 30, 2026. [Online]. Available: https://www.sbb.gov.tr/kalkinma-planlari/
62. [62] CDC Strategic Planning Workgroup, “Biological and chemical terrorism: Strategic plan for preparedness and response. Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR),” 49:RR–4, Apr. 2000.
63. [63] Mehmet Baysallar and Levent Kenar, “Biyoterörizm ve Dekontaminasyon Yönetimi,” Türk Hijyen ve Deneysel Biyoloji Dergisi, vol. 63, no. 1, pp. 115–128, 2006.
64. [64] Y. Y. B. OTLU and Elif Seren TANRİVERDİ, “Features of COVID-19 Agent,” Mikrobiyoloji ve COVID-19, vol. 1. Baskı, pp. 7–14, 2020.
65. [65] WHO, “Description of Coronavirus.” [Online]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19
66. [66] WHO, “COVID-19 Dashboard.” Accessed: Sep. 15, 2022. [Online]. Available: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses
67. [67] L.-M. Yan, S. Kang, and S. Hu, “Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route”.
68. [68] N. L. Oluka, “Bio-terrorism Strategy in the Wuhan Coronavirus Pandemic: A Perspective from Conspiratorial and Apocalyptic Hypotheses”.
69. [69] F. Castro-Chavez, “Anticovidian v.2 COVID-19: Hypothesis of the Lab Origin Versus a Zoonotic Event which can also be of a Lab Origin,” 2020.
70. [70] K.-S. Yuen, Z.-W. Ye, S.-Y. Fung, C.-P. Chan, and D.-Y. Jin, “SARS-CoV-2 and COVID-19: The most important research questions,” Cell Biosci, vol. 10, no. 1, p. 40, Dec. 2020.
71. [71] K. G. Andersen, A. Rambaut, W. I. Lipkin, E. C. Holmes, and R. F. Garry, “The proximal origin of SARS-CoV-2,” Nat Med, vol. 26, no. 4, pp. 450–452, Apr. 2020.
72. [72] D. Cyranoski, “Inside the Chinese lab poised to study world’s most dangerous pathogens,” Nature, vol. 542, no. 7642, pp. 399–400, Feb. 2017.
73. [73] A. Dehghani and G. Masoumi, “Could SARS-CoV-2 or COVID-19 Be a Biological Weapon?,” ijph, Jul. 2020.
74. [74] D. Knight, “COVID-19 Pandemic Origins: Bioweapons and the History of Laboratory Leaks,” Southern Medical Journal, vol. 114, no. 8, pp. 465–467, Aug. 2021.
75. [75] H. Akbaba, G. Erel-Akbaba, and S. Senturk, “Special Focus Issue Part II: Recruitment of Solid Lipid Nanoparticles for The Delivery of CRISPR/Cas9: Primary Evaluation of Anticancer Gene Editing,” Nanomedicine (Lond.), vol. 16, no. 12, pp. 963–978, May 2021.
76. [76] H. Akbaba, G. Erel-Akbaba, Y. Başpınar, and Ş. Şentürk, “Design of Liposome